

**Additional file 2:** Auto-antibodies at Time point 2 in 118 MCTD patients

<b>Antibody status at time point 2*</b>	<b>Stable MCTD phenotype N = 104</b>	<b>Diagnostic converters N = 14</b>
Anti-RNP antibodies	78 (75)	7 (50)
Anti-RNP, U/mL, Mdn (IQR)	61 (9 – 240)	15 (3 – 37)
Anti-dsDNA antibodies**	3 (3)	6 (43)
Anti-Sjögrens Syndrome antigen A (anti-SSA)	18 (17)	6 (43)
Anti-Sjögrens Syndrome antigen B (anti-SSB)	4 (4)	1 (7)
Anti-topoisomerase I (anti-scl70)	0	1 (7)
Anti-centromere protein-B (ACA)	0	3 (21)
Anti-histidyl-tRNA synthetase (anti-Jo1)	0	2 (14)
Anti-Smith (anti-Sm)**	7 (7)	1 (7)
Low complements	6 (6)	6 (43)
Anti-citrullinated protein antibodies (ACPA)**	5 (5)	4 (29)

\*presented as N (%) unless otherwise specified. \*\*The patients categorized as stable MCTD patients had only weakly positive anti-dsDNA antibodies, anti-Smith antibodies or anti-citrullinated protein antibodies, combined with strongly positive anti-RNP antibodies in addition to MCTD features. Weakly positive anti-dsDNA antibodies, anti-Smith antibodies or low complements did not occur together in the patients categorized as stable MCTD patients.